Massive ex vivo expansion of human natural regulatory T cells (T regs) with minimal loss of in vivo functional activity

Science Translational Medicine

Volumn 3, Issue 83, 2011, Pages

  Hippen, Keli L ^a   Merkel, Sarah C ^a   Schirm, Dawn K ^a   Sieben, Christine M ^a   Sumstad, Darin ^b   Kadidlo, Diane M ^b   McKenna, David H ^b   Bromberg, Jonathan S ^c   Levine, Bruce L ^d   Riley, James L ^d   June, Carl H ^d   Scheinberg, Phillip ^e   Douek, Daniel C ^e   Miller, Jeffrey S ^a   Wagner, John E ^a   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CD86 ANTIGEN; FC RECEPTOR; TRANSCRIPTION FACTOR FOXP3; LEUKOCYTE ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; CELL EXPANSION; CELL ISOLATION; CONTROLLED STUDY; EX VIVO STUDY; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTE CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; UMBILICAL CORD BLOOD; CYTOLOGY; IMMUNOLOGY; IMMUNOPHENOTYPING;

ANTIGENS, CD; HUMANS; IMMUNOPHENOTYPING; T-LYMPHOCYTES, REGULATORY;

EID: 79956258982     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001809     Document Type: Article

References (39)

1. L. A. Welniak, B. R. Blazar, W. J. Murphy, Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu. Rev. Immunol. 25, 139-170 (2007).
2. R. S. Wildin, A. Freitas, IPEX and FOXP3: Clinical and research perspectives. J. Autoimmun. 25, 56-62 (2005).
3. + regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196, 389-399 (2002).
4. + regulatory T cells. Immunol. Rev. 212, 60-73 (2006).
5. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99, 3493-3499 (2002).
6. + T cells. Curr. Opin. Immunol. 15, 690-696 (2003).
7. + cells. Semin. Immunol. 18, 78-88 (2006).
8. + immunoregulatory T cells: Central players in the arena of peripheral tolerance. Semin. Immunol. 16, 81-88 (2004).
9. M. G. Roncarolo, M. Battaglia, Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 7, 585-598 (2007).
10. high regulatory cells in human peripheral blood. J. Immunol. 167, 1245-1253 (2001).
11. + T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 104, 453-461 (2004).
12. K. L. Hippen, P. Harker-Murray, S. B. Porter, S. C. Merkel, A. Londer, D. K. Taylor, M. Bina, A. Panoskaltsis-Mortari, P. Rubinstein, N. Van Rooijen, T. N. Golovina, M. M. Suhoski, J. S. Miller, J. E. Wagner, C. H. June, J. L. Riley, B. R. Blazar, Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 112, 2847-2857 (2008).
13. C. G. Brunstein, J. S. Miller, Q. Cao, D. H. McKenna, K. L. Hippen, J. Curtsinger, T. Defor, B. L. Levine, C. H. June, P. Rubinstein, P. B. McGlave, B. R. Blazar, J. E. Wagner, Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 117, 1061-1070 (2011).
14. high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 108, 4260-4267 (2006).
15. S. Karakhanova, M. Munder, M. Schneider, M. Bonyhadi, A. D. Ho, M. Goerner, Highly efficient expansion of human CD4+CD25+ regulatory T cells for cellular immunotherapy in patients with graft-versus-host disease. J. Immunother. 29, 336-349 (2006).
16. + regulatory T cells upon repetitive in vitro stimulation. Eur. J. Immunol. 39, 1088-1097 (2009).
17. + regulatory T cells allows for their purification from expansion cultures. Blood 113, 5125-5133 (2009).
18. + regulatory T cells for clinical trials. Biol. Blood Marrow Transplant. 12, 267-274 (2006).
19. high T cells for immunotherapy. PLoS One 3, e2233 (2008).
20. + regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 177, 8338-8347 (2006).
21. + regulatory T cells. Blood 105, 4743-4748 (2005).
22. + regulatory T cells. Blood 107, 1018-1023 (2006).
23. + regulatory T cells cultured with rapamycin. J. Immunol. 178, 320-329 (2007).
24. + T reg cells. J. Exp. Med. 203, 1701-1711 (2006).
25. T. N. Golovina, T. Mikheeva, M. M. Suhoski, N. A. Aqui, V. C. Tai, X. Shan, R. Liu, R. R. Balcarcel, N. Fisher, B. L. Levine, R. G. Carroll, N.Warner, B. R. Blazar, C. H. June, J. L. Riley, CD28 costimulation is essential for human T regulatory expansion and function. J. Immunol. 181, 2855-2868 (2008).
26. B. L. Levine, W. B. Bernstein, M. Connors, N. Craighead, T. Lindsten, C. B. Thompson, C. H. June, Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J. Immunol. 159, 5921-5930 (1997).
27. J. Huehn, J. K. Polansky, A. Hamann, Epigenetic control of FOXP3 expression: The key to a stable regulatory T-cell lineage? Nat. Rev. Immunol. 9, 83-89 (2009).
28. J. C. Rathmell, E. A. Farkash, W. Gao, C. B. Thompson, IL-7 enhances the survival and maintains the size of naive T cells. J. Immunol. 167, 6869-6876 (2001).
29. + T cells. Blood 101, 2711-2720 (2003).
30. + T cell priming in naive mice. Immunity 33, 942-954 (2010).
31. G. Beriou, C. M. Costantino, C. W. Ashley, L. Yang, V. K. Kuchroo, C. Baecher-Allan, D. A. Hafler, IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 113, 4240-4249 (2009).
32. + antigen-specific autoimmune effectors in vitro and in vivo. J. Immunol. 181, 3137-3147 (2008).
33. + T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211, 214-224 (2006).
34. P. Scheinberg, J. J. Melenhorst, J. M. Brenchley, B. J. Hill, N. F. Hensel, P. K. Chattopadhyay, M. Roederer, L. J. Picker, D. A. Price, A. J. Barrett, D. C. Douek, The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood 114, 5071-5080 (2009).
35. A. L. Putnam, T. M. Brusko, M. R. Lee, W. Liu, G. L. Szot, T. Ghosh, M. A. Atkinson, J. A. Bluestone, Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 58, 652-662 (2009).
36. + T cells. J. Immunol. 177, 944-949 (2006).
37. J. E. Foley, J. Mariotti, K. Ryan, M. Eckhaus, D. H. Fowler, Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells. Biol. Blood Marrow Transplant. 14, 959-972 (2008).
38. pos regulatory T cells differentiate into IL-17-producing cells. Blood 112, 2340-2352 (2008).
39. Acknowledgments: We would like to thank C. Nelson for assistance with animal husbandry. Funding: This work was supported in part by research grants from the Children's Cancer Research Fund and Blood and Marrow Transplant Research Fund to K.L.H.; Leukemia and Lymphoma Translational Research (grant R6029-07), R37 HL56067, and P01 AI056299 to B.R.B., P01 CA067493 and N01HB037164 to B.R.B., J.E.W., and J.S.M.; support from Miltenyi Biotec to B.R.B. and J.E.W.; a grant from Becton Dickinson to J.E.W.; and support from the JDRF Collaborative Centers for Cell Therapy and the JDRF Center on Cord Blood Therapies for Type 1 Diabetes to J.L.R. and C.H.J. Author contributions: K.L.H. designed the research, performed the experiments, interpreted the data, and wrote the paper. S.C.M., D.K.S., C.M.S., and P.S. performed the experiments, interpreted the data, and assisted with the paper. D.S. and D.M.K. performed the research. J.S.M., J.E.W., D.C.D., D.H.M., J.S.B., B.L.L., C.H.J., and J.L.R. designed the research and wrote the paper. B.R.B. designed the research, interpreted the data, and wrote the paper. Competing interests: J.L.R., C.H.J., and J.E.W. have research funding from Becton Dickinson and C.H.J. and B.R.B. were previously scientific consultants for Becton Dickinson, although this funding did not conflict with this manuscript. K.L.H., J.L.R., C.H.J., and B.R.B. are authors on U.S. provisional patent application number 61/322, 186, "Methods to expand a T regulatory cell master cell bank." The other authors declare that they have no competing interests.